Obicetrapib - NewAmsterdam Pharma
Alternative Names: AMG 899; DEZ 001; obicetripib; TA-8995Latest Information Update: 19 Jul 2024
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Amgen; Mitsubishi Tanabe Pharma Corporation; NewAmsterdam Pharma
- Class Antidementias; Antihyperlipidaemics; Heterocyclic compounds; Quinolines; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Dyslipidaemias; Hyperlipoproteinaemia type IIa
- Phase II Alzheimer's disease; Hypercholesterolaemia
Most Recent Events
- 11 Jul 2024 NewAmsterdam Pharma plans a phase II VINCENT trial for Dyslipidemias (Monotherapy, Combination therapy) in August 2024(NCT06496243)
- 12 Jun 2024 NewAmsterdam has patent protection for "Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof" in USA
- 09 Apr 2024 NewAmsterdam Pharma completes enrolment in the Phase-III clinical trials in Dyslipidaemias (In adults, In the elderly, Treatment-experienced) in South Africa, Croatia, Georgia, Jordan, Latvia, United Kingdom, Poland, Netherlands, Japan, Italy, Israel, Germany, Slovakia, Spain, Hungary, Finland, Denmark, China, Czech Republic, Canada, Bulgaria, USA, Australia (PO) (NCT05202509) (EudraCT2021-005092-39)